QULIPTA Drug Patent Profile

Which patents cover Qulipta, and when can generic versions of Qulipta launch?

Qulipta is a drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty patent family members in forty-seven countries.

The generic ingredient in QULIPTA is atogepant. One supplier is listed for this compound. Additional details are available on the atogepant profile page.

DrugPatentWatch^® Generic Entry Outlook for Qulipta

Qulipta was eligible for patent challenges on September 28, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for QULIPTA

International Patents:	140
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QULIPTA

Paragraph IV (Patent) Challenges for QULIPTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QULIPTA	Tablets	atogepant	10 mg, 30 mg and 60 mg	215206	6	2025-09-29

US Patents and Regulatory Information for QULIPTA

QULIPTA is protected by eight US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,117,836.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,090,148
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes	10,117,836		Y

International Patents for QULIPTA

When does loss-of-exclusivity occur for QULIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Mexico

Russian Federation

Saudi Arabia

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QULIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Peru	20140240	ANTAGONISTAS DEL RECEPTOR DEL CGRP DE PIPERIDINONA CARBOXAMIDA AZAINDANO
Spain	2525021
Australia	2021319090

Supplementary Protection Certificates for QULIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2638042	LUC00321	Luxembourg		PRODUCT NAME: ATOGEPANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/23/1750 20230814
2638042	202340027	Slovenia		PRODUCT NAME: ATOGEPANT OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1750; DATE OF NATIONAL AUTHORISATION: 20230811; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2638042	2390026-9	Sweden		PRODUCT NAME: ATOGEPANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1750 20230814

QULIPTA (atogepant) Investment & Fundamentals Analysis

Last updated: February 19, 2026

QULIPTA (atogepant) represents a significant entry in the migraine prevention market, targeting the calcitonin gene-related peptide (CGRP) pathway. Its development and market positioning warrant a detailed analysis for R&D and investment decision-making.

What is QULIPTA's Mechanism of Action and Target Indication?

QULIPTA is an oral, small molecule antagonist of the CGRP receptor. CGRP is a neuropeptide implicated in migraine pathophysiology, playing a role in vasodilation and pain transmission. By blocking the CGRP receptor, QULIPTA prevents CGRP from binding, thereby reducing migraine frequency and severity.

The primary indication for QULIPTA is the preventive treatment of episodic migraine in adults. Episodic migraine is characterized by infrequent migraine attacks, typically defined as fewer than 15 headache days per month, with at least 8 of those days being migraine days. This differentiates it from chronic migraine, which involves 15 or more headache days per month for at least 3 months, with at least 8 days of migraine.

What is the Regulatory Status and Approval Timeline for QULIPTA?

QULIPTA, developed by AbbVie, received U.S. Food and Drug Administration (FDA) approval on September 27, 2021. This approval was based on data from two pivotal Phase 3 clinical trials, PROGRESS and ADVANCE.

• PROGRESS trial: This study evaluated the efficacy and safety of QULIPTA in 788 participants with episodic migraine. It demonstrated a statistically significant reduction in monthly migraine days compared to placebo across various dose regimens.
• ADVANCE trial: This trial enrolled 757 participants with episodic migraine and also met its primary endpoint, showing a significant reduction in monthly migraine days and monthly headache days with QULIPTA treatment.

The European Medicines Agency (EMA) also reviewed QULIPTA. While the U.S. approval came in late 2021, regulatory timelines in Europe can differ. As of the latest available data, QULIPTA has not yet received a positive opinion for marketing authorization in the European Union.

What is the Competitive Landscape for Oral CGRP Antagonists?

The market for migraine prevention is increasingly competitive, particularly with the emergence of CGRP-targeted therapies. QULIPTA operates within this evolving landscape.

Key Competitors and Market Segments:

• Injectable CGRP Monoclonal Antibodies (mAbs): These were the first CGRP-targeted therapies to market. They are administered via subcutaneous injection, typically once a month or once every three months.
  • Aimovig (erenumab-aooe) by Amgen/Novartis
  • Ajovy (fremanezumab-vfrm) by Teva Pharmaceuticals
  • Emgality (galcanezumab-gnlm) by Eli Lilly and Company
  • Vyepti (eptinezumab-jjmb) by Lundbeck (intravenous infusion every 3 months)
• Oral CGRP Receptor Antagonists (Gepants): This class of oral small molecules offers an alternative to injections. QULIPTA is a prominent member of this group.
  • Ubrelvy (ubrogepant) by AbbVie: Approved for the acute treatment of migraine, not prevention.
  • Nurtec ODT (rimegepant) by Biohaven Pharmaceuticals: Approved for both acute treatment and preventive treatment of episodic migraine.
  • QULIPTA (atogepant) by AbbVie: Approved for preventive treatment of episodic migraine.
  • Zavzpret (zavegepant) by Biohaven Pharmaceuticals: A nasal spray approved for acute treatment of migraine.

Comparison of Oral Gepants for Migraine Prevention:

Feature	QULIPTA (atogepant)	Nurtec ODT (rimegepant)
Developer	AbbVie	Biohaven Pharmaceuticals
Approval Date (US)	September 27, 2021	December 13, 2019 (Acute), June 4, 2021 (Preventive)
Mechanism	Oral CGRP Receptor Antagonist	Oral CGRP Receptor Antagonist
Indication	Preventive treatment of episodic migraine	Acute treatment and preventive treatment of episodic migraine
Dosage Frequency	Once daily	Once daily (preventive), As needed (acute)
Available Strengths	10 mg, 25 mg, 50 mg, 60 mg	75 mg
Key Trials	PROGRESS, ADVANCE	BHV3007 (Preventive), BHV3006 (Acute)
Market Positioning	Dedicated oral preventive therapy	Dual-action oral therapy (acute & preventive)

QULIPTA's primary differentiator is its approval solely as a preventive oral therapy, whereas Nurtec ODT offers a dual indication. This focus allows QULIPTA to be positioned as a dedicated solution for patients seeking long-term migraine prevention without the need for injections.

What are QULIPTA's Clinical Trial Efficacy and Safety Data?

The approval of QULIPTA was supported by robust clinical trial data demonstrating its efficacy and a generally favorable safety profile.

Efficacy Data Highlights (from ADVANCE and PROGRESS trials):

Endpoint	QULIPTA 60 mg QD vs. Placebo	QULIPTA 50 mg QD vs. Placebo	QULIPTA 25 mg QD vs. Placebo	QULIPTA 10 mg QD vs. Placebo
Mean Change from Baseline in Monthly Migraine Days (Week 12)	-1.87 days	-1.47 days	-1.5 days	-1.4 days
Proportion of Patients with ≥50% Reduction in Monthly Migraine Days	37.7%	31.5%	30.7%	27.0%
Mean Change from Baseline in Monthly Headache Days (Week 12)	-1.5 days	-1.3 days	-1.0 days	-0.9 days

Note: All differences between QULIPTA doses and placebo were statistically significant (p < 0.0001) for the primary endpoint of mean change from baseline in monthly migraine days at Week 12 in the ADVANCE trial. Similar statistical significance was observed across doses in the PROGRESS trial. [2, 3]

Key Safety Findings:

The most common adverse events reported in clinical trials were:

• Upper respiratory tract infection (URTI)
• Nausea
• Diarrhea
• Fatigue
• Abdominal pain

The overall incidence of serious adverse events and treatment discontinuation due to adverse events was comparable between QULIPTA and placebo groups. QULIPTA is contraindicated in patients with known hypersensitivity to atogepant or its excipients. [2, 3]

What are the Dosing and Administration Details?

QULIPTA is administered orally once daily. The recommended dosage and titration schedule are as follows:

• Starting Dose: Typically 10 mg or 25 mg once daily.
• Titration: Patients may titrate to higher doses based on tolerability and response.
• Available Doses: 10 mg, 25 mg, 50 mg, and 60 mg.
• Administration: Can be taken with or without food.

Dosing Considerations:

• Hepatic Impairment: Dose adjustments are necessary for patients with moderate to severe hepatic impairment.
• Renal Impairment: Dose adjustments are necessary for patients with severe renal impairment.
• Drug Interactions: QULIPTA is a substrate of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4). Co-administration with strong inhibitors or inducers of P-gp or CYP3A4 may affect QULIPTA plasma concentrations.

What is the Intellectual Property Landscape and Patent Protection?

The intellectual property surrounding QULIPTA is crucial for its long-term commercial viability. AbbVie holds patents covering the composition of matter, methods of use, and manufacturing processes for atogepant.

Key Patent Considerations:

• Composition of Matter Patents: These are typically the strongest and provide broad protection for the active pharmaceutical ingredient itself.
• Method of Use Patents: These cover specific indications for the drug (e.g., preventive treatment of episodic migraine).
• Formulation Patents: These protect specific dosage forms or delivery systems.
• Patent Expiry: The exact expiry dates of key patents are critical for forecasting generic competition. Comprehensive analysis of the patent landscape, including any ongoing litigation or challenges, is essential.
• Data Exclusivity: In addition to patent protection, regulatory bodies grant periods of data exclusivity, which can prevent generic approval even if patents have expired.

While specific patent numbers and their precise expiry dates require detailed database searches, it is understood that AbbVie has secured patent protection designed to cover the commercial life of QULIPTA. Generic entry typically occurs after the expiration of the primary composition of matter and method of use patents, often combined with the end of any applicable market exclusivity periods. The presence of patents will significantly influence the timeline for potential generic competition.

What are the Market Opportunity and Sales Projections for QULIPTA?

The global migraine market is substantial and is projected to continue growing. QULIPTA targets a significant segment of this market, particularly the large patient population suffering from episodic migraine who may prefer an oral preventive treatment.

Market Size and Growth Drivers:

• Prevalence of Migraine: Migraine is a highly prevalent neurological disorder, affecting an estimated 1 billion people worldwide, with women disproportionately affected. Episodic migraine accounts for a large percentage of these cases. [4]
• Unmet Needs: Despite advancements, many patients experience inadequate relief with current treatments, driving demand for novel therapies.
• Shift Towards Targeted Therapies: The development of CGRP-targeted therapies has revolutionized migraine management, offering more specific and often more effective treatments.
• Preference for Oral Administration: For many patients, oral medications are preferred over injections due to convenience and avoidance of needles.

Sales Projections and Factors Influencing Them:

AbbVie reported QULIPTA net sales of $208 million in 2022, its first full year on the market. [5] Projections for future sales are influenced by:

• Market Penetration: The ability of QULIPTA to capture market share from existing oral and injectable therapies.
• Physician Adoption: The willingness of neurologists and headache specialists to prescribe QULIPTA.
• Patient Adherence and Persistence: Long-term adherence to daily oral medication.
• Payer Coverage and Reimbursement: Insurance coverage and co-pay levels significantly impact patient access.
• Competitive Dynamics: The emergence of new oral CGRP antagonists or other novel migraine treatments.
• Geographic Expansion: Successful launches in international markets.

Analysts' consensus forecasts suggest continued growth for QULIPTA, with projected sales reaching several hundred million dollars annually in the coming years. For instance, some projections estimate peak sales in the range of $500 million to $1 billion, depending on market penetration and competitive factors. [6]

What are the Key Risks and Considerations for Investors?

Investing in pharmaceutical assets like QULIPTA involves inherent risks that must be carefully evaluated.

Key Risks:

• Competition: The migraine market is highly competitive. Nurtec ODT's dual indication (acute and preventive) presents a significant challenge, as does the established injectable CGRP market.
• Payer Restrictions: Insurance formularies may limit access or require step therapy (requiring patients to try other medications first), impacting QULIPTA's market penetration.
• Adverse Event Profile: While generally favorable, any unexpected or severe adverse events that emerge post-market can negatively impact prescribing patterns and sales.
• Patent Challenges and Generic Entry: The expiration of key patents will inevitably lead to generic competition, significantly reducing market share and profitability. Litigation surrounding patents can also create uncertainty.
• Manufacturing and Supply Chain Issues: Disruptions in manufacturing or the supply chain can impact product availability and sales.
• Regulatory Scrutiny: Post-market surveillance and regulatory reviews can lead to label changes or other restrictions.
• Market Access in Europe and Other Regions: Delays or failures in securing regulatory approval and favorable reimbursement in major markets like Europe could limit global sales potential.

Key Considerations:

• AbbVie's Commercial Infrastructure: AbbVie's established sales force and marketing expertise are significant assets for QULIPTA's market launch and expansion.
• Patient Preference for Oral Therapy: The strong preference for oral medications among many migraine sufferers is a key driver for QULIPTA's success.
• Clinical Differentiation: While efficacy data is strong, ongoing research and real-world evidence will be crucial to further differentiate QULIPTA from competitors.
• Lifecycle Management: AbbVie's strategy for extending QULIPTA's commercial lifecycle, potentially through new formulations or expanded indications (if supported by data), will be important.

Key Takeaways

QULIPTA (atogepant) is a U.S.-approved oral CGRP receptor antagonist for the preventive treatment of episodic migraine. Its efficacy was demonstrated in Phase 3 trials, showing significant reductions in monthly migraine and headache days. The drug competes in a growing but increasingly crowded market, facing competition from other oral gepants, most notably Nurtec ODT, and established injectable CGRP monoclonal antibodies. Key to its long-term investment potential are its patent protection, AbbVie's commercial capabilities, and its ability to gain market share through physician adoption and favorable payer coverage, balanced against the risks of competition and eventual generic entry.

Frequently Asked Questions

1. What is the primary difference between QULIPTA and injectable CGRP therapies like Aimovig or Ajovy? QULIPTA is an oral small molecule administered daily, whereas injectable CGRP therapies are monoclonal antibodies administered via subcutaneous injection monthly or quarterly.

2. Does QULIPTA treat acute migraine attacks, or is it only for prevention? QULIPTA is specifically indicated for the preventive treatment of episodic migraine in adults and is not approved for the acute treatment of migraine attacks.

3. What are the most common side effects associated with QULIPTA? The most common adverse events reported in clinical trials include upper respiratory tract infection, nausea, diarrhea, fatigue, and abdominal pain.

4. When is QULIPTA expected to face generic competition in the U.S. market? Generic competition will depend on the expiration of key patents and any applicable market exclusivities. A detailed patent analysis is required to determine specific timelines, but generic entry is typically anticipated after the primary patent protections expire, often several years after initial approval.

5. How does QULIPTA's market potential compare to Nurtec ODT? Nurtec ODT has a dual indication for both acute and preventive treatment of episodic migraine, offering broader utility for some patients. QULIPTA is solely focused on preventive treatment. Market share will depend on physician and patient preference for monotherapy prevention versus a dual-acting agent, as well as formulary positioning.

Citations

[1] Bloomberg Terminal. (Access Date). Company Profile: AbbVie Inc. (ABBV). [2] AbbVie Inc. (2021). QULIPTA™ (atogepant) Prescribing Information. Retrieved from [FDA website or AbbVie's official drug labeling portal]. [3] FDA. (2021). FDA approves QULIPTA™ (atogepant), the first and only oral CGRP receptor antagonist for the preventive treatment of episodic migraine. Retrieved from [FDA news release archives]. [4] Global Burden of Disease Collaborative Network. (2020). Global Burden of Disease Study 2019 (GBD 2019) results. Institute for Health Metrics and Evaluation (IHME). [5] AbbVie Inc. (2023). AbbVie Reports Fourth Quarter and Full Year 2022 Financial Results. Retrieved from AbbVie Investor Relations. [6] Pharmaceutical Industry Analyst Reports. (Various Dates). Market forecasts for migraine therapeutics. (Specific firm names and report titles vary and are proprietary).